Scavenger Receptor Class B type I (SR-BI） Inhibitor
-
SMS121
0 ImagesCat. No.: HY-163541Purity: 99.06%SMS121 is a CD36 inhibitor with a KD values of about 5 µM. SMS121 reduces the uptake of lipids and inhibits cell viability in acute myeloid leukemia cells. SMS121 has antitumor activity.
-
ITX5061
0 ImagesITX5061 is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis.
-
Anti-CD36 Antibody
0 ImagesCat. No.: HY-P990352Purity: 99.43%Synonyms: Ona36Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
-
ML278
0 ImagesCat. No.: HY-19616CAS No.: 1604821-43-3ML278 is a scavenger receptor-BI (SR-BI) inhibitor with an IC50 of 0.93 nM in mice. ML278 inhibits SR-BI-mediated lipid uptake, enhances the binding of high-density lipoprotein (HDL) to SR-BI, blocks the uptake of oleoylcholesteryl ester from HDL, and reversibly inhibits the efflux of free cholesterol to HDL particles. ML278 can be used in studies related to atherosclerotic coronary artery disease.
-
ITX5061 free base
0 ImagesCat. No.: HY-122068CAS No.: 848144-15-0ITX5061 free base is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 free base increases HDL-C levels by inhibiting SR-BI activity. ITX5061 free base also moderately elevates ApoA-I levels. ITX5061 free base reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 free base can be used in the research of atherosclerosis.
-
BLT-3
0 ImagesCat. No.: HY-120433CAS No.: 109940-24-1BLT-3 is an inhibitor of scavenger receptor class B type I (SR-BI) that exerts reversible, non-cell-type-specific inhibitory effects on SR-BI-mediated lipid transport. BLT-3 inhibits SR-BI-mediated selective lipid uptake from HDL as well as cholesterol efflux from cells to HDL. BLT-3 enhances the binding of HDL to SR-BI. BLT-3 is applicable to research related to atherosclerosis and coronary heart disease.
-
PLT012
0 ImagesCat. No.: HY-P991911Purity: 98.90%PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8+ tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8+ T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research.
-
HDL376
0 ImagesSynonyms: SDZ-HDL 376HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease.
-
ML279
0 ImagesCat. No.: HY-124666CAS No.: 1604821-55-7ML279 is a potent scavenger receptor, class B, type I (SR-BI) inhibitor. ML279 can inhibit SR-BI-mediated lipid uptake by stabilizing the binding of HDL to SR-BI (EC50 = 0.27 μM). ML279 can be used for the researches of infection and cardiovascular disease, such as atherosclerosis and HCV infection.
